Showing 2921-2930 of 3415 results for "".
- Abeona Submits BLA for RDEB Treatmenthttps://practicaldermatology.com/news/abeona-submits-bla-for-rdeb-treatment/2462026/Abeona Therapeutics Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). <
- Arcutis Submits NDA for Roflumilast Cream 0.15% for AD Treatmenthttps://practicaldermatology.com/news/arcutis-submits-nda-for-roflumilast-cream-015-for-ad-treatment/2462001/Arcutis Biotherapeutics, Inc. submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis (AD) in adults and children ages 6 years and older. Roflumilast cream is
- Study Sheds Light on Why Wounds Heal Poorly in People With Diabeteshttps://practicaldermatology.com/news/study-sheds-light-on-why-wounds-heal-poorly-in-people-with-diabetes/2461989/When exosomes are defective in diabetic patients, they can drive inflammation and impair healing of wounds, according to a new Nano Today study led by University of Pittsburgh and UPMC researchers
- Interim INTEGUMENT-OLE Results: Arcutis’ Roflumilast Cream 0.15% Performs Well in ADhttps://practicaldermatology.com/news/arcutis-roflumilast-cream-015-performs-well-in-ad/2461987/Roflumilast cream 0.15% showed durable and improved efficacy over time and a favorable safety profile in mild to moderate Atopic Dermatitis (AD), according to interim results from the INTEGUMENT-OLE long-term open-label study. Arcutis intends to submit a supplemental New Drug Applicatio
- Tarsus Rolls Out XDEMVY for Demodex Blepharitishttps://practicaldermatology.com/news/tarsus-rolls-out-xdemvy-for-demodex-blepharitis/2461985/Tarsus Pharmaceuticals, Inc. is rolling out XDEMVY, the First and Only US Food and Drug Administration-approved treatment for Demodex blepharitis. XDEMVY is now available at pharmacies nationwide for prescription. Bobak Azamian, MD, PhD, Chief Executive Officer, and Chairman, ran
- Are Wealthy People at Higher Risk for Skin Cancer?https://practicaldermatology.com/news/are-wealthy-people-are-more-prone-to-skin-cancer/2461972/Wealthier people are at greater risk for melanoma, according to new research in Cancers. “A higher socio-economic status is known to be associated with more vacations in sunny climates and recreational tanning, which likely ultimately drives melanoma incidence in this pop
- FDA Clears Sofwave’s SUPERB Technology for Treating Acne Scarshttps://practicaldermatology.com/news/fda-clears-sofwaves-superb-technology-for-treating-acne-scars/2461969/The U.S. Food and Drug Administration (FDA) has cleared Sofwave’s SUPERB technology for treating acne scars. “Gaining FDA clearance to market SUPERB for the treatment of acne scarring not only paves the way to positively impact patients seeking improved appearances
- China's NMPA Accepts Akeso’s NDA for Ebdarokimab in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/chinas-nmpa-accepts-akesos-nda-for-ebdarokimab-in-moderate-to-severe-plaque-psoriasis/2461958/Akeso Inc.’s New Drug Application (NDA) for its fully human IgG1monoclonal antibody ebdarokimab (IL-12/lL-23, AK101) for the treatment of adults with moderate-to-severe plaque psoriasis has been accepted by the National Center for Drug Evaluation of the State Drug Administration of the
- Verrica Supports FDA’s Warning Letters to Retailers Selling Unapproved Molluscum Contagiosum Treatmentshttps://practicaldermatology.com/news/verrica-supports-fdas-warning-letters-to-retailers-selling-unapproved-molluscum-contagiosum-treatments/2461954/Verrica Pharmaceuticals Inc. supports the U.S. Food and Drug Administration’s (FDA’s) recent action against retailers and manufacturers of unapproved products for the treatment of molluscum contagiosum. “On the heels of the June 1, 2023 FDA warning to consumers not to
- Sentient’s Tixel Receives FDA Nod for Treatment of Periorbital Wrinkleshttps://practicaldermatology.com/news/sentients-tixel-receives-fda-nod-for-treatment-of-periorbital-wrinkles/2461945/The device combines heat with the forward motion of a medical-grade titanium tip. The U.S. Food and Drug Administration has approved